Jordan Cohen: Key Findings from Cancer Institute NSW Summit 2025
Jordan Cohen, Medical Oncologist at Calvary Mater Newcastle, shared a post on LinkedIn:
“I had a great opportunity this week to attend first Cancer Institute NSW Summit in Sydney.
In keeping with the conference theme of equity, innovation and personalised care we presented work from The Kinghorn Cancer Centre highlighting the sociodemographic factors of patients referred for early phase clinical trials.
Key findings:
– 442 patients have enrolled onto early phase clinical trials since 2017.
– 111 (28%) patients came from regional and rural locations.
– Telehealth use in regional and rural patients for first consults was over 50%.
– Only a small proportion of those enrolled were culturally or linguistically diverse, from low socioeconomic locations, and identified as being from an Aboriginal or Torres Strait Islander background.
Early phase clinical trials are a valuable treatment option in oncology care in Australia but are only accessed by select patients. Ongoing efforts to ensure equitable and individually supported access is underway. Watch this space!”
More posts featuring Cancer Institute NSW Summit 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023